CTLA4 gene variants in autoimmunity and cancer: A comparative review

Iranian Journal of Immunology

Volumn 8, Issue 3, 2011, Pages 127-149

  Ghaderi, Abbas ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmunity; Cancer; CTLA4; Immune balance; Polymorphism

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HLA DR ANTIGEN;

3' UNTRANSLATED REGION; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 2; CTLA4 GENE; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEOPLASM; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 80054115387     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006; 24:65-97.
2. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol. 2000: 164:5015-8.
3. Yao Q, Fischer KP, Motyka B, Ferland S, Li L, Tyrrell DL, et al. Identification of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) isoforms in the Pekin duck. Dev Comp Immunol. 2010; 34:749-58.
4. Buonavista N, Balzano C, Pontarotti P, Le Paslier D, Golstein P. Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics. 1992; 13:856-61.
5. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999; 162:5784-91.
6. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev. 2005; 204:102-15.
7. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996; 5:1075-80.
8. Park JH, Chang HS, Park CS, Jang AS, Park BL, Rhim TY, et al. Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE. Am J Respir Crit Care Med. 2007; 175:775-82.
9. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003; 423:506-11.
10. Atabani SF, Thio CL, Divanovic S, Trompette A, Belkaid Y, Thomas DL, et al. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol. 2005; 35:2157-62.
11. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An Mse I RFLP in the human CTLA4 promotor.Biochem Biophys Res Commun. 1996; 225:817-8.
12. Mao HT, Wang XB, Zhang L, Gu HT. [Studies on the genetic pathogenesis of myasthenia gravis caused by CTLA-4 gene polymorphism]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004; 21:574-8.
13. Hudson LL, Rocca K, Song YW, Pandey JP. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet. 2002; 111:452-5.
14. Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J, et al. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 2003; 4:132-7.
15. Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE, Clarke AE. A population-based assessment of systemic lupus erythematosus incidence and prevalence--results and implications of using administrative data for epidemiological studies. Rheumatology (Oxford). 2007; 46:1814-8.
16. Heward JM, Allahabadia A, Carr-Smith J, Daykin J, Cockram CS, Gordon C, et al. No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clin Endocrinol (Oxf). 1998; 49:331-4.
17. Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol. 2003; 64:936-40.
18. Chua KH, Puah SM, Chew CH, Tan SY, Lian LH. Study of the CTLA-4 gene polymorphisms in systemic lupus erythematosus (SLE) samples from Malaysia. Ann Hum Biol. 2010; 37:274-80.
19. Lee YH, Kim YR, Ji JD, Sohn J, Song GG. Polymorphisms of the CTLA-4 exon 1 and promoter gene in systemic lupus erythematosus. Lupus. 2001; 10:601-5.
20. Liu MF, Wang CR, Lin LC, Wu CR. CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus. 2001; 10:647-9.
21. Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, et al. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford). 2001; 40:662-7.
22. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004; 12:620-6.
23. Lee YH, Harley JB, Nath SK. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet. 2005; 116:361-7.
24. Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, et al. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum. 2004; 50:748-52.
25. Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology (Oxford). 2000; 39:63-6.
26. Vaidya B, Pearce SH, Charlton S, Marshall N, Rowan AD, Griffiths ID, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford). 2002; 41:180-3.
27. Rodriguez MR, Nunez-Roldan A, Aguilar F, Valenzuela A, Garcia A, Gonzalez-Escribano MF. Association of the CTLA4 3' untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol. 2002; 63:76-81.
28. Yanagawa T, Gomi K, Nakao EI, Inada S. CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol. 2000; 27:2740-2.
29. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A. CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens. 1999; 53:296-300.
30. Seidl C, Donner H, Fischer B, Usadel KH, Seifried E, Kaltwasser JP, et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens. 1998; 51:62-6.
31. Lee CS, Lee YJ, Liu HF, Su CH, Chang SC, Wang BR, et al. Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol. 2003; 22:221-4.
32. Han S, Li Y, Mao Y, Xie Y. Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Hum Genet. 2005; 118:123-32.
33. Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, et al. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet. 2005; 13:823-8.
34. Yanagawa T, Maruyama T, Gomi K, Taniyama M, Kasuga A, Ozawa Y, et al. Lack of association between CTLA-4 gene polymorphism and IDDM in Japanese subjects. Autoimmunity. 1999; 29:53-6.
35. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab. 1995; 80:41-5.
36. Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, et al. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab. 1999; 84:2398-401.
37. Maalej A, Bougacha N, Rebai A, Bellassouad M, Ayadi-Makni F, Abid M, et al. Lack of linkage and association between autoimmune thyroid diseases and the CTLA-4 gene in a large Tunisian family. Hum Immunol. 2001; 62:1245-50.
38. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA, Gough SC. Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid. 2002; 12:3-6.
39. Tomoyose T, Komiya I, Takara M, Yabiku K, Kinjo Y, Shimajiri Y, et al. Cytotoxic T-lymphocyte antigen-4 gene polymorphisms and human T-cell lymphotrophic virus-1 infection: their associations with Hashimoto's thyroiditis in Japanese patients. Thyroid. 2002; 12:673-7.
40. Villanueva R, Inzerillo AM, Tomer Y, Barbesino G, Meltzer M, Concepcion ES, et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid. 2000; 10:791-8.
41. Yanagawa T, Taniyama M, Enomoto S, Gomi K, Maruyama H, Ban Y, et al. CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid. 1997; 7:843-6.
42. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet. 1999; 8:1195-9.
43. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf). 1997; 46:551-4.
44. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, et al. Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid. 2000; 10:453-9.
45. Kinjo Y, Takasu N, Komiya I, Tomoyose T, Takara M, Kouki T, et al. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J Clin Endocrinol Metab. 2002; 87:2593-6.
46. Kalantari T, Mostafavi H, Pezeshki AM, Farjadian S, Doroudchi M, Yeganeh F, et al. Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. Autoimmunity. 2003; 36:313-6.
47. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J Clin Endocrinol Metab. 2007; 92:3162-70.
48. Erdman SE, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol. 2010; 38:76-87.
49. Van der Auwera BJ, Vandewalle CL, Schuit FC, Winnock F, De Leeuw IH, Van Imschoot S, et al. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin Exp Immunol. 1997; 110:98-103.
50. Takara M, Komiya I, Kinjo Y, Tomoyose T, Yamashiro S, Akamine H, et al. Association of CTLA-4 gene A/G polymorphism in Japanese type 1 diabetic patients with younger age of onset and autoimmune thyroid disease. Diabetes Care. 2000; 23:975-8.
51. Cosentino A, Gambelunghe G, Tortoioli C, Falorni A. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann N Y Acad Sci. 2002; 958:337-40.
52. Krokowski M, Bodalski J, Bratek A, Machejko P, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to IDDM in a population from central Poland. Diabetes Metab. 1998; 24:241-3.
53. Fajardy I, Vambergue A, Stuckens C, Weill J, Danze PM, Fontaine P. CTLA-4 49 A/G dimorphism and type 1 diabetes susceptibility: a French case-control study and segregation analysis. Evidence of a maternal effect. Eur J Immunogenet. 2002; 29:251-7.
54. Ma Y, Tang X, Chang W, Gao L, Li M, Yan W. CTLA-4 gene A/G polymorphism associated with diabetes mellitus in Han Chinese. Chin Med J (Engl). 2002; 115:1248-50.
55. Genc S, Genc K, Sercan O, Kizildag S, Gulay Z, Atay T, et al. Analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism in patients with type 1 diabetes mellitus in a Turkish population. J Pediatr Endocrinol Metab. 2004; 17:731-5.
56. Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A. CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diabetes Res Clin Pract. 2005; 68:111-6.
57. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis. Am J Epidemiol. 2005; 162:3-16.
58. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics. 2008; 60:275-86.
59. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol. 1999; 97:182-90.
60. Dyment DA, Steckley JL, Willer CJ, Armstrong H, Sadovnick AD, Risch N, et al. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study. J Neuroimmunol. 2002; 123:193-8.
61. Roxburgh RH, Sawcer S, Maranian M, Seaman S, Hensiek A, Yeo T, et al. No evidence of a significant role for CTLA-4 in multiple sclerosis. J Neuroimmunol. 2006; 171:193-7.
62. Fukazawa T, Kikuchi S, Miyagishi R, Niino M, Yabe I, Hamada T, et al. CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol. 2005; 159:225-9.
63. Greve B, Simonenko R, Illes Z, Peterfalvi A, Hamdi N, Mycko MP, et al. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Mult Scler. 2008;14:153-8.
64. Wray BN, Stankovich J, Whittock L, Dwyer T, Ponsonby AL, van der Mei IA, et al. CTLA-4 and multiple sclerosis: the A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. J Neuroimmunol. 2008; 196:139-42.
65. Bagos PG, Karnaouri AC, Nikolopoulos GK, Hamodrakas SJ. No evidence for association of CTLA-4 gene polymorphisms with the risk of developing multiple sclerosis: a meta-analysis. Mult Scler. 2007; 13:156-68.
66. Yousefipour G, Erfani N, Momtahan M, Moghaddasi H, Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand. 2009; 120:424-9.
67. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol. 2008; 20:707-12.
68. Alizadeh BZ, Broen J, Rueda B, Hesselstrand R, Wuttge D, Simeon C, et al. Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). J Rheumatol. 2010; 37:1673-9.
69. Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg. 2009; 33:710-5.
70. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: A nationwide population based cohort study. Br J Dermatol. 2010; 163:800-6.
71. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010; 42:426-9.
72. Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K. Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol. 2002; 20:823-8.
73. Hudson LL, Silver RM, Pandey JP. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol. 2004; 31:85-7.
74. Rajaee A, Ebrahimi A, Ghiam AF, Kalantari T, Ghaderi A. Exon-1 polymorphism of ctla-4 gene is not associated with systemic sclerosis in Iranian patients. Rheumatol Int. 2006; 26:687-92.
75. Almasi S, Erfani N, Mojtahedi Z, Rajaee A, Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun. 2006; 7:401-6.
76. Takeuchi F, Nakaue N, Kawasugi K, Mori M, Kuwata S, Tanimoto K. The CTLA-4 -1661A/G and -1772T/C dimorphisms in Japanese patients with systemic sclerosis. Rheumatol Int. 2007; 27:785-7.
77. Balbi G, Ferrera F, Rizzi M, Piccioli P, Morabito A, Cardamone L, et al. Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis. Clin Exp Immunol. 2007; 149:40-7.
78. Wang XB, Kakoulidou M, Qiu Q, Giscombe R, Huang D, Pirskanen R, et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun. 2002; 3:46-9.
79. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol. 2002; 130:224-32.
80. Wang XB, Pirskanen R, Giscombe R, Lefvert AK. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med. 2008; 263:61-9.
81. Fernandez-Mestre M, Sanchez K, Balbas O, Gendzekhzadze K, Ogando V, Cabrera M, et al. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol. 2009; 70:532-5.
82. Chuang WY, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol. 2005; 58:644-8.
83. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: a review of 903 case records. Public Health. 2000; 114:143-5.
84. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother. 2010; 33:557-69.
85. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010; 3:15-25.
86. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, et al. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat. 2004; 86:1-7.
87. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet. 2006; 165:114-20.
88. Li H, Fu ZK, Wang LH, Li DL, Wu N, Zhang J, et al. [Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms with susceptibility to breast cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008; 24:282-4.
89. Wang L, Li D, Fu Z, Li H, Jiang W. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer. 2007; 7:173.
90. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res. 2008; 68:7025-34.
91. Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, Ghaderi A. Increased CTLA-4 and FOXP3 Transcripts in Peripheral Blood Mononuclear Cells of Patients with Breast Cancer. Pathol Oncol Res. 2010; 16:547-51.
92. Erfani N, Razmkhah M, Ghaderi A. Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer. Cancer Invest. 2010; 28:828-32.
93. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007; 68:698-704.
94. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol. 2007; 22:2283-7.
95. Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet. 2008; 35:317-21.
96. Solerio E, Tappero G, Iannace L, Matullo G, Ayoubi M, Parziale A, et al. CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. Dig Liver Dis. 2005; 37:170-5.
97. Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, et al. CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis. 2010; 25:39-45.
98. Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, et al. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep. 2010; 37:515-20.
99. Lankarani KB, Karbasi A, Kalantari T, Yarmohammadi H, Saberi-Firoozi M, Alizadeh-Naeeni M, et al. Analysis of cytotoxic T lymphocyte associated antigen 4 gene polymorphisms in patients with ulcerative colitis. J Gastroenterol Hepatol. 2006; 21:449-53.
100. Khaghanzadeh N, Erfani N, Ghayumi MA, Ghaderi A. CTLA4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet. 2010; 196:171-4.
101. Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis. 2007; 28:1237-40.
102. Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, Jonkisz A, Tomkiewicz A, et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol. 2010; 71:195-200.
103. Rahimifar S, Erfani N, Sarraf Z, Ghaderi A. CTLA-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol. 2010; 119:136-9.
104. Hu L, Liu J, Chen X, Zhang Y, Liu L, Zhu J, et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol. 2010; 71:888-91.
105. Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol. 2004; 76:14-8.
106. Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma. Br J Haematol. 2005; 129:784-90.
107. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, et al. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol. 2007; 136:237-48.
108. Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, Urbaniak-Kujda D, et al. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Hum Immunol. 2008; 69:193-201.
109. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2006; 24:3483-9.
110. Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med. 2006;35:51-4.
111. Kammerer PW, Toyoshima T, Schoder F, Kammerer P, Kuhr K, Brieger J, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol. 2010; 46:543-8.
112. Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, Nelson HH. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res. 2009;69:6158-63.
113. Xiao M, Qi F, Chen X, Luo Z, Zhang L, Zheng C, et al. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population. Int J Immunogenet. 2010; 37:27-32.
114. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009; 113:1581-8.
115. Gendzekhadze K, Rivas-Vetencourt P, Montano RF. Risk of adverse post-transplant events after kidney allograft transplantation as predicted by CTLA-4 +49 and TNF-alpha -308 single nucleotide polymorphisms: a preliminary study. Transpl Immunol. 2006; 16:194-9.
116. Krichen H, Sfar I, Jendoubi-Ayed S, Makhlouf M, Ben Rhomdhane T, Bardi R, et al. Genetic polymorphisms of immunoregulatory proteins in acute renal allograft rejection. Transplant Proc. 2009; 41:3305-7.
117. Kusztal M, Koscielska-Kasprzak K, Drulis-Fajdasz D, Magott-Procelewska M, Patrzalek D, Janczak D, et al. The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. Transpl Immunol. 2010; 23:121-4.
118. Azarian M, Busson M, Lepage V, Charron D, Toubert A, Loiseau P, et al. Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations. Blood. 2007; 110:4623-4.
119. Piccioli P, Balbi G, Serra M, Morabito A, Lamparelli T, Gobbi M, et al. CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. Ann Hematol. 2010; 89:613-8.
120. Perez-Garcia A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R, et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia. 2009; 23:486-91.
121. Vannucchi AM, Guidi S, Guglielmelli P, Glinz S, Lombardini L, Busca A, et al. Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007; 40:1001-2.
122. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008; 105:19396-401.
123. Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol. 2010; 40:569-78.
124. Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009; 69:6011-4.